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Aims and method A series of eleven patients prescribed intramuscular clozapine at
five UK sites is presented. Using routinely collected clinical data, we describe the use,
efficacy and safety of this treatment modality.
Results We administered 188 doses of intramuscular clozapine to eight patients.
The remaining three patients accepted oral medication. With the exception of minor
injection site pain and nodules, side-effects were as expected with oral clozapine, and
there were no serious untoward events. Nine patients were successfully established
on oral clozapine with significant improvement in their clinical presentations.
Clinical implications Although a novel formulation in the UK, we have shown that
intramuscular clozapine can be used safely and effectively when the oral route is
initially refused.
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Clozapine remains the gold-standard intervention for
treatment-resistant schizophrenia (TRS), offering a wide
range of benefits.1–5 Case reports and series describing the
use of intramuscular clozapine for patients unable or unwill-
ing to take oral treatment have been published from authors
based in Israel, the Netherlands and Australia.6–9 Although
it is possible to successfully administer clozapine via a naso-
gastric tube as an alternative to the oral route, the more con-
ventional option of an injection is usually preferable if a
suitable preparation is available.10 Reports of the use of
both intramuscular and nasogastric clozapine show that
this ‘assertive’ approach can often result in improvements
in mental state and a reduction in incidents and segregation,
as well as facilitating progression to a less-restrictive envir-
onment. Also in practice, a stated intention to use ‘enforced’
nasogastric or intramuscular clozapine is often sufficient
to persuade patients to accept the less intrusive oral
route.11,12 Clozapine remains an underused treatment and
‘enforced’ clozapine in particular has been seen as contro-
versial in the UK.13–15 The use of, and attitudes to, intramus-
cular clozapine in the UK have, to date, been described
in poster presentations only.16–18 We now present the use
of intramuscular clozapine in five UK settings with eleven
in-patients.
Method
Data was collected between January 2017 and July 2018 at
five UK sites: two medium-secure units, two high-secure
hospitals and a locked rehabilitation unit. Clinical records
were used to identify patients prescribed intramuscular clo-
zapine, and their demographics, previous, response to cloza-
pine use, use of oral and intramuscular therapy, subsequent
response as assessed by clinical team impressions, adverse
effects from intramuscular treatment and subsequent stabil-
isation on oral therapy were recorded. Pharmacy staff were
consulted to report on the nurses’ practical experience of
using the intramuscular formulation.
How to use intramuscular clozapine
Clozapine preparation and availability
Clozapine for injection is an unlicensed ‘special’ product
made in the Netherlands by Brocacef and imported to the
UK by Durbin PLC via Mawdsleys. The minimum order
quantity is two packs of ten 125mg/5mL ampoules costing
approximately £2000 in total. Hospital pharmacy depart-
ments have experienced delays with importation, supply
shortages and stock being sent with a shelf life of only
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2 months. When new, the ampoules have a 2-year shelf life
in the dark at 25°C.
Legal authority
In England and Wales, incapacitous or non-consenting
patients detained under the Mental Health Act (1983) may
be administered drug treatments for mental disorders for
longer than 3 months only if a second opinion appointed
doctor approves the treatment, including the route of admin-
istration. A rationale needs to be given for the use of
unlicensed preparations and so, even if the current authority
includes oral and/or intramuscular antipsychotics, a separ-
ate request for this preparation will be required. The legal
authority to allow enforced blood taking as part of clozapine
treatment is provided by section 63 of the Mental Health Act
(1983) as long as there is valid authority for the clozapine
treatment itself.19
Administration and dosing
Administration is by deep intramuscular injection.
Depending on the volume of injection, the gluteal, lateral
thigh or deltoid injections sites were used in this series.
The Brocacef preparation has no UK licence. The
Netherlands licence specifies that volumes of 2–4mL should
be administered into the gluteal muscle and not the arm or
thigh, and that volumes >4mL should be given as separate
injections. There is no evidence base to favour one site
over another. Teams may choose to split doses exceeding
4mL.20 As the bioavailability is approximately twice that
of oral preparations, oral doses are halved and injections
are usually given once daily. Given the practical limits of
administering large volumes of intramuscular medication
initial plans for titrations up to volumes of 3.5 mL (87.5 mg
intramuscular clozapine is equal to 175mg oral clozapine)
may require flexibility, depending on the response. This
would enable the use of intramuscular clozapine beyond
the initial 14-day titration.
Liaison with clozapine monitoring services
Although the intramuscular preparation is an unlicensed
product, the aim is to establish the patient on oral clozapine
as quickly as possible, with as little intramuscular use as
possible (preferably none). The treating psychiatrist, phar-
macy and patient will need to be registered with a clozapine
monitoring service so as to allow oral clozapine to be dis-
pensed. In practice, patients have been registered with a
monitoring service. Oral clozapine has been prescribed
and, if refused, then intramuscular injections of clozapine
administered. Blood monitoring at the required intervals
continues, so ensuring that the patient remains registered
and that oral clozapine can be dispensed. The clozapine
patient-monitoring service manufacturing the relevant oral
brand of clozapine has no responsibility for the use of intra-
muscular clozapine. Our series involved patents registered
with all current UK clozapine providers.
Available protocols and guidelines
Several trusts have produced guidelines and suggested dos-
ing schedules for the use of intramuscular clozapine,
which are available online.21
Results
Patient characteristics
All eleven patients identified were male: ten had a primary
diagnosis of schizophrenia (ICD-10 code F20)22 and one
had a primary diagnosis of bipolar disorder (ICD-10 code
F31).22 The indication for clozapine was treatment resist-
ance following previous failed treatments, including high
dose and antipsychotic polypharmacy. Most had demon-
strated a response to clozapine treatment previously, but
had discontinued owing to various patient or clinician vari-
ables: complaints about blood monitoring, sedation, and a
coincidental fall in platelet count owing to immune
thrombocytopenia. At least two patients had experienced
severe rebound psychosis when oral clozapine was stopped.
All the units included have a smoke-free policy, which had
been instigated before the data collection period, and so all
patients were non-smokers. See Table 1 for a summary of
the patient demographics.
Use of intramuscular clozapine
In three patients the offer to choose between the oral and
intramuscular route was sufficient to establish oral clozapine
maintenance treatment at between 400 and 425mg/day,
with significant benefit. In the remaining eight patients
intramuscular clozapine was required, and between 1 and
99 doses were administered per patient, predominantly
into the gluteal muscle, with one being given into the lateral
thigh after a patient developed nodules in the gluteal muscle,
and one into the deltoid muscle when the patient refused to
have the clozapine by any other route (it was the first dose at
only 0.25 mL, and no additional effects were noted). Seven
patients resisted intramuscular administration to the extent
that restraint was used on between one and nine occasions
during the initial 14-day dose titration. Restraint was
required to take a blood sample in two individuals, one on
five occasions and the other on four occasions, and there
were no adverse effects during restraint. The remaining
patients did not resist. By the end of 5 months, nine patients
had been established on oral clozapine, the majority of these
showing improvement at doses between 150mg and 400mg/
day (mean 228mg/day). No serious adverse effects occurred
owing to either the injection itself or associated episodes of
restraint. Minor injection site pain occurred in three
patients; one experienced sedation, and the patient who
had 99 doses of intramuscular clozapine experienced some
injection site nodules. There were no injection site abscesses
or infections. The maximum reported dose of intramuscular
clozapine administered was 250mg in 10mL, which was
given across three injection sites. Tables 2 and 3 describe
the use of intramuscular clozapine in this series.
Serum levels were obtained from two patients who had
intramuscular clozapine continuously for five or more
days; see Table 4. The levels were consistent with the
equivalent oral doses.23 With regards to target plasma
levels, all units aimed for the usual recommended plasma
range, 0.35–0.6 mg/L, but then would be guided by individ-
ual patient symptoms and side-effects; higher than usual
levels were used in certain cases.
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Prescribing and administering experiences
Nurses were familiar with the practice of intramuscular
antipsychotics and in general terms the procedure was per-
ceived as acceptable: the injection solution was reportedly
easy to draw up and, despite the bright yellow colour of
the solution, the syringe markings were clearly readable
and administration was easy, with very little resistance
against the plunger when administering.
Nurses needed reassurance and reminding about max-
imum volume for single intramuscular administration, so
when, for example, 10mL was administered, three injections
(4mL + 3mL + 3mL) were used. Overall, nurses reported
that they were confident in their ability to administer intra-
muscular clozapine.
Doctors required advice on bioequivalence of oral and
intramuscular clozapine and how to word the prescription
so that it was clear the intramuscular was only to be used
if oral was declined. They also occasionally needed to be
reminded to document the rationale for intramuscular treat-
ment in clinical notes and in the associated care plan.
Assistance was sometimes needed, especially initially, to
complete the required application and gain approval by
trust approval bodies.
In the unit where nasogastric clozapine had also previ-
ously been used, the procedure for administering intramus-
cular was seen as much simpler, faster and less stressful for
patients. However, the limitations on dosing with the intra-
muscular formulation owing to volume considerations were
a perceived disadvantage in patients who had experienced
Table 1 Patient demographics
Patient
Age at first episode of
psychosis (years)
Age at this admission
(years)







1 17 24 7 Poor 1100 MSU
2 28 34 6 Partial 350 MSU
3 22 39 17 Partial 325 HSS
4 23 37 14 N/A N/A HSS
5 21 47 26 N/A N/A MSU
6 17 37 20 Yes 250 MSU
7 18 30 12 Yes 600 MSU
8 22 36 14 Partial 200 HSS
9 20 31 11 Yes Not known HSS
10 13 50 37 Yes Not known HSS
11 18 38 20 N/A N/A Rehab
Mean 20 37 17 471
MSU, medium-secure unit; HSS, high-secure services; N/A, not applicable; Rehab, low-secure unit.
Table 2 Use of intramuscular clozapine: titration over initial 14-day protocol (see section How to use intramuscular clozapine)
Patient Route of first clozapine dose Oral clozapine doses in titration Intramuscular clozapine doses in titration Restraint
1 Oral 9 5 5
2 Oral 0 14 4
3 Intramuscular 10 4 2
4 Oral 13 1 7
5 Oral 13 1 1
6 Oral 14 0 0
7 Oral 14 0 0
8 Oral 14 0 6
9 Oral 14 0 0
10 Intramuscular 0 14 2
11 Intramuscular 0 14 0
Mean 9.2 5.8 2
Total 101 53 22
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benefit and were poorly compliant on higher doses after the
initial titration.
Discussion
When presented with a patient with TRS who refuses cloza-
pine and consequently faces distress, disability, risk and a
potentially extended length of stay, clinicians can feel that
they are dealing with an impossible problem.5 Alternatives
to clozapine are unlikely to work and may well cause
harm, although a cycle of depot changes, high dose or poly-
pharmacy regimes may still be attempted.24,25 ‘Enforced’
clozapine (i.e. via nasogastric or intramuscular) is a rarity
and, but for the handful of case series above, barely
described in the literature; there is believed to be no previ-
ous published experience of its use in the UK. Although
some NHS trusts have published guidelines for the use of
intramuscular clozapine, these do not provide for all eventu-
alities and will likely need adapting to local and individual
patient circumstances, often while treatment is taking
place; indeed, a flexible and pragmatic approach is more
likely to succeed. Difficult decisions will include not only
deciding whether to use the intramuscular route at the out-
set, but also when to stop treatment. Neither oral clozapine
nor intramuscular clozapine will provide a solution to every
patient with TRS; for example, the intramuscular route may
result in patient benefit, but not within the time frame or
ceiling dose allowed within a protocol agreed by the govern-
ance structure of the institution. In these cases the clinical
team may need to consider higher doses and/or multiple
intramuscular clozapine injections over the course of the
day. A higher-strength solution for injection would be very
useful and could enable intramuscular clozapine to be
given as the doses increase during the titration, and to con-
tinue at higher maintenance doses if the oral dose is refused
later in the treatment. Presently one unit in the study pre-
scribes intramuscular clozapine doses lower than the equiva-
lent oral dose if 48 h of non-adherence is approaching,
essentially to prevent the need for retitration. An alternative
would include the nasogastric route; however, nasogastric
administration of clozapine is culturally less acceptable
and less routine than intramuscular in mental health set-
tings. With nasogastric administration, more time is needed
in the restraint position, therefore reducing patient safety,
and there is a risk the patient could vomit up the medica-
tion. The clinical team needs to consider whether the bene-
fits of improvement, possibly in the long term, justify the
short-term risks of daily restraint or the complications of
using an unlicensed, relatively unused intramuscular drug
treatment. Although in our series there were no adverse out-
comes from the episodes of restraint, it does not necessarily
follow that the procedure is devoid of risk. Our series is
unusual compared to the experience elsewhere in that
greater number of patients had a much higher number of
injections. In the Israeli and Dutch series most patients
were established on oral clozapine after one intramuscular
dose only, almost all within 2 weeks of starting treatment
with clozapine, and only one had treatment for 3 months.
It is possible that our sites, which were all secure units,
selected for a patient cohort that was more clinically com-
plex and hence more difficult to treat.
In conclusion, given the lack of new treatments for TRS
in recent years, it is essential that clinicians deliver the
treatments that are likely to work, and clozapine in particu-
lar. The intramuscular route can be used to remove one of
the impediments to its use, namely refusal of oral treat-
ment. Although our experience was in secure settings, the
use of intramuscular antipsychotic medication is used
throughout different mental health settings and there is
no reason to suggest that ‘enforced’ clozapine, whether
using the intramuscular or any other route, should be con-
fined to secure services. As was found in the series from the
Netherlands and with nasogastric clozapine in the UK,
many patients accept oral clozapine when faced with the
coercive alternative, which is ultimately the desired out-
come. There has been concern that the procedure itself
might be aversive and painful; however, reports of injection
site pain and inflammation were very low. We have demon-
strated that the use of intramuscular clozapine, although
not without some drawbacks, is overall easy, safe and
effective.
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150 300 0.26 0.11
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